Skip to content

Contact +44 (0) 20 7060 7474 email us

Cancer

Hematological Cancers - A Therapeutic & Competitive Insight

 

Publication Date October 2006
Publisher Bioseeker
Product Type Report
Pages 196
ISBN Number not applicable
Product Code BSK00133

Price

£2,645.00
approximately: $4,005 | €2,952

pdf

Buy Now

print

Buy Now

Order above formats by FAX

Order by Fax

Summary

Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin's disease (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin's lymphoma. The world prevalence is approximately 650,000 cases, of which 300,000 are low grade and 350,000 are aggressive. The lymphoma market is a complex topic and several pitfalls await actors not well prepared. BioSeeker Group will guide through this field and bring structure and knowledge enables our customers to analyze opportunities. This report will help to answer questions on the subject of additional lymphoma treatments beyond Rituxan.

As well, leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry. This has now clearly changed with the launch of Novartis' Gleevec (imatinib mesylate) for chronic myeloid leukemia, which is presenting the industry with proof that development within the leukemia market produces lucrative returns. Gleevec saw sales rise of 32 percent to $2.2 billion during 2005. Consequently, the historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected.

Research and analysis highlights

  • BioSeeker Group has studied the progress of 125 of the most prominent drugs in development for the treatment of hematological cancers. The most actively discussed and interesting drugs were selected and presented. A collection of emerging facts suggest that numerous of the new targeted therapies are agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated in particular ways before or after cytotoxic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.
  • This extensive 190+ pages report not only describes and analyzes the latest years of progress in lymphoma and leukemia, it also provides an insight and framework to understand this complex field. In this report, BioSeeker provides one of the most comprehensive coverage of the R&D trends to set the future marketplace. We present both an overview and a detailed description on the progress of 100 key drugs in Phase II and III development, together with general descriptions on drugs and targets. Among these drugs BioSeeker clearly sees a substantial progress for some while others have failed. There will be a more intense competition in several of the sub-markets and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report

  • Thorough examination of status and impact of several novel drugs in development
  • Discussion of the challenges in current and future treatment strategies
  • Anticancer pipeline of most companies in the field

Key reasons to read this report

  • Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in R&D, and the results of clinical trials to date.
  • Gain insight into the current challenges and commercial opportunities associated with therapy for the hematological cancers.
  • More than 190 high quality references.

Some of the drugs included in this analysis

AG-858, Aldesleukin , Alemtuzumab, AP23573, Apolizumab, Arsenic trioxide, Atra, Avastin, BAY 43-9006, Bevacizumab, BiovaxID , Bortezomib , CEP-701, Ceplene, Clofarabine, Cloretazine, CMC-544 , Decitabine, Enzastaurin , Epratuzumab, FavId , FK228, Flavopiridol, Gemtuzumab, Genasense, Gvax, IDEC-114 , Imatinib, Marqibo, MyVax, Nelarabine , OSI-461, Pixantrone , PKC412, PTK787, Rituximab, SGN-30, SGN-40 , SU5416, Temsirolimus , Troxacitabine, Valspodar, VELCADE, Xcytrin, Zanolimumab, Zarnestra etc.

Some of the companies included in this analysis

Abgenix (Amgen), Accentia BioPharmaceuticals, Antigenics, Bayer, Bioenvision, Biogen Idec, BTG, Cell Genesys, Cell Therapeutics, Cephalon, Chiron (now Novartis) Corporation, Corixa (GSK), Cyclacel Group (Cyclacel), Eli Lilly, Exelixis, Favrille, Genentech, Genitope, Genmab, Genta, GlaxoSmithKline, Immunomedics, Inex Pharmaceuticals, Johnson & Johnson, Millennium Pharmaceuticals, Novartis, Pharmacyclics, Protein Design Labs, Roche, Sanofi-Aventis, Schering-Plough, Seattle Genetics, SuperGen, Vion Pharmaceuticals, Wyeth etc.

Contents

  • 1. Executive Summary
  • 2. Methodology
  • 3. Table of Contents
    • 3.1 List of Boxes
    • 3.2 List of Tables
  • 4. The Lymphomas
    • 4.1 Introduction
      • 4.1.1 Disease Definition
      • 4.1.2 Etiology & Pathophysiology
    • 4.2 Epidemiology
    • 4.3 Current Treatment Strategies
      • 4.3.1 Hodgkin's Disease
      • 4.3.2 Radiation Therapy
      • 4.3.3 Chemotherapy
      • 4.3.4 Transplantation
      • 4.3.5 Treatment Option Overview
    • 4.4 Non-Hodgkin's Lymphoma
      • 4.4.1 Radiation Therapy
      • 4.4.2 Chemotherapy
      • 4.4.3 Immunotherapy
      • 4.4.4 Bone Marrow and Peripheral Blood Transplants
      • 4.4.5 Watch and Wait
      • 4.4.6 Treatment Option Overview
    • 4.5 Prognosis
      • 4.5.1 Hodgkin's Disease
      • 4.5.2 Non-Hodgkin
    • 4.6 Progress in Current Treatment Strategies
      • 4.6.1 Hodgkin
      • 4.6.2 Non-Hodgkin
      • 4.6.3 Rituxan
      • 4.6.4 Bexxar
      • 4.6.5 Zevalin
    • 4.7 Key Therapeutic Strategies for Future Treatments
      • 4.7.1 Therapy Type, Targets & Mechanisms
    • 4.8 Competitive Landscape in Drug Development: The Late Stage Pipeline
    • 4.9 Current Drug Development: The Early Stage Pipeline
  • 5. The Leukemias
    • 5.1 Introduction
      • 5.1.1 Disease Definitions
      • 5.1.2 Etiology & Pathophysiology
      • 5.1.3 The Lymphoid Malignancies
      • 5.1.4 The Myeloid Malignancies
    • 5.2 Epidemiology
    • 5.3 Prognosis
      • 5.3.1 The Lymphoid Malignancies
      • 5.3.2 The Myeloid Malignancies
    • 5.4 Current Treatment Strategies
      • 5.4.1 The Lymphoid Malignancies
      • 5.4.2 The Myeloid Malignancies
    • 5.5 Progress in Current Treatment Strategies
      • 5.5.1 The Lymphoid Malignancies
      • 5.5.2 The Myeloid Malignancies
    • 5.6 Key Therapeutic Strategies for Future Therapies
      • 5.6.1 Therapeutic Type, Targets & Mechanisms
    • 5.7 Competitive Landscape in Drug Development: The Late Stage Pipeline
      • 5.7.1 The Lymphoid Malignancies
      • 5.7.2 The Myeloid Malignancies
    • 5.8 Current Drug Development: The Early Stage Pipeline
      • 5.8.1 The Myeloid Malignancies
      • 5.8.2 The Lymphoid Malignancies
    • 5.9 Disclaimer
      • 5.9.1 Liability
      • 5.9.2 Completeness
  • 6. Appendix: Drugs Approved for the Treatment of Leukemia: a Historical Perspective
  • 7. Drug Index
  • 8. Company Index
  • List of Boxes
    • Box 1: Possible Complications of Treatment
    • Box 2: Updated REAL/WHO Classification for B-Cell Neoplasms
    • Box 3: Subclassification of Stage
    • Box 4: Updated REAL/WHO Classification for B-Cell Neoplasms
    • Box 5: Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms
    • Box 6: Staging Subclassification System
    • Box 7 Study Details
    • Box 8: Major Treatment Regimes
    • Box 9: CLL Staging System
    • Box 10: Quick Facts - Clofarabine
    • Box 11: Quick Facts - Alemtuzumab
    • Box 12: Quick Facts - Gemtuzumab
    • Box 13: Quick Facts - Imatinib
    • Box 14: Quick Facts - Rituximab
    • Box 15: Quick Facts - Genasense
    • Box 16: Quick Facts - Flavopiridol
    • Box 17: Quick Facts - Atra
    • Box 18: Quick Facts - Gvax
    • Box 19: Quick Facts - Zarnestra
    • Box 20: Quick Facts - BAY 43-9006
    • Box 21: Quick Facts - Ceplene
    • Box 22: Quick Facts - Valspodar
    • Box 23: Quick Facts - CEP-701
    • Box 24: Quick Facts - PKC412
    • Box 25: Quick Facts - SU5416
    • Box 26: Quick Facts - PTK787
    • Box 27: Quick Facts - Cloretazine
    • Box 28: Company Statement on Progress
    • Box 29: Quick Facts - Troxacitabine
    • Box 30: Quick Facts - FK228
    • Box 31: Quick Facts - Decitabine
    • Box 32: Quick Facts - VELCADE
    • Box 33: Velcade Sales 2005
    • Box 34: Quick Facts - AG-858
    • Box 35: Quick Facts - Avastin
    • Box 36: Quick Facts - OSI-461
    • Box 37: Quick Facts - Xcytrin
    • Box 38: Quick Facts - AP23573
  • List of Tables
    • Table 1: Drugs Used in the Treatment of Lymphoma
    • Table 2 Summary of Strategies Enhancing Antibody Function
    • Table 3 Cancer Immunotherapy Strategies
    • Table 4: Protein Kinase Targets in Clinical Trials for Lymphoma
    • Table 5: Near Term Progress Aldesleukin
    • Table 6: Near Term Progress Arsenic trioxide
    • Table 7: Near Term Progress BiovaxID
    • Table 8: Near Term Progress Bortezomib
    • Table 9: Near Term Progress Epratuzumab
    • Table 10: Near Term Progress FavId
    • Table 11: Near Term Progress MyVax
    • Table 12: Near Term Progress Nelarabine
    • Table 13: Near Term Progress Genasense
    • Table 14: Near Term Progress Pixantrone
    • Table 15: Near Term Progress Temsirolimus
    • Table 16: Near Term Progress Zanolimumab
    • Table 17: Near Term Progress Flavopiridol
    • Table 18: Near Term Progress Bevacizumab
    • Table 19: Near Term Progress CMC-544
    • Table 20: Near Term Progress Galiximab
    • Table 21: Near Term Progress LY317615
    • Table 22: Near Term Progress SGN-40
    • Table 23: Near Term Progress Apolizumab
    • Table 24: Near Term Progress SGN-30
    • Table 25: ALL Classification
    • Table 26: Latest Approved Drugs for the Treatment of Leukemia
    • Table 27: Kinase Inhibitors in Development for the Treatment of Leukemia
    • Table 28: Near Term Progress Rituximab
    • Table 29: Near Term Progress Oblimersen
    • Table 30: Near Term Progress Alvocidib
    • Table 31: Near Term Progress ATRA
    • Table 32: Near term progress GVAX
    • Table 33: Near tearm progress HuM195
    • Table 34: Near term progress Zarnestra
    • Table 35: Near Term Progress Sorafenib
    • Table 36: Near Term Progress Valspodar
    • Table 37: Summary of Current Late Stage Pipeline
    • Table 38: Near term progress CEP-701
    • Table 39: Near Term Progress PKC412
    • Table 40: Near Term Progress SU5416
    • Table 41: Near Term Progress PTK787
    • Table 42: Near Term Progress VNP40101M
    • Table 43: Near Term Progress Troxacitabine
    • Table 44: Near Term Progress Decitabine
    • Table 45 Near Term Progress Bortezomib
    • Table 46 Near Term Progress AG-858
    • Table 47: Near Term Progress Bevacizumab
    • Table 48: Near Term Progress OSI-461
    • Table 49: Near Term Progress Xcytrin
    • Table 50: Near Term Progress AP23573
    • Table 51: Summary of Current Early Stage Pipeline